Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Leonard Appleman, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00630409
First received: February 28, 2008
Last updated: January 17, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2009
  Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)